Semaglutide vs Liraglutide: Research Comparison | Peptide Intel Hub

Semaglutide is a 31-amino-acid GLP-1 analogue with an aminoisobutyric-acid substitution at position 8 (Aib8) that blocks DPP-4 cleavage, plus a C18 fatty-di-acid modification via a spacer at Lys26 that promotes strong albumin binding and extends the half-life to ~7 days.

Liraglutide is a shorter-acting GLP-1 analogue with a single C16 fatty-acid modification at Lys26 and Arg substitution at position 34 — engineered for once-daily research cadence rather than weekly. It shares the core GLP-1 sequence but differs in the fatty-acid engineering that governs pharmacokinetics.

Both compounds are selective GLP-1 receptor agonists with no meaningful GIP or glucagon receptor activity. Semaglutide's engineering delivers stronger receptor occupancy and a longer duration than liraglutide at matched research doses.

Liraglutide is the reference first-generation GLP-1 analogue for translational research that leverages the earlier clinical literature (LEAD, SCALE programmes). Semaglutide is the reference second-generation compound with the SUSTAIN, STEP and SELECT programmes as the translational backbone.

Semaglutide has an approximate half-life of 165 hours (~7 days) supporting weekly research cadence. Liraglutide has an approximate half-life of 13 hours supporting once-daily cadence.

The difference is driven entirely by the fatty-acid engineering — the C18 di-acid + spacer in semaglutide binds albumin substantially more strongly than the C16 mono-acid in liraglutide.

Semaglutide is the dominant GLP-1 research reference for weekly-cadence protocols, chronic-exposure metabolic studies and any research design leveraging the SUSTAIN / STEP / SELECT literature.

Liraglutide remains the reference for daily-cadence GLP-1 research, for translational work that reuses the LEAD / SCALE / LEADER literature, and for research designs that need a shorter-acting GLP-1 arm alongside a longer-acting comparator.

Both Semaglutide and Liraglutide ship from Regena Peptides only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds are published on the Regena Peptides lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena Peptides COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C only if the vial will not be reconstituted within 8–12 months. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Semaglutide and Liraglutide benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose semaglutide when the protocol requires weekly-cadence GLP-1 receptor activation with extended chronic exposure, or when reusing the SUSTAIN / STEP clinical literature is part of the project design. Researchers choose liraglutide when a daily-cadence GLP-1 arm is needed, when the LEAD / SCALE literature is the translational reference, or when comparator studies need both generational analogues in matched arms.

For multi-compound comparator studies, the Regena Peptides consultations team will reserve matched-batch inventory of both Semaglutide and Liraglutide against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both Semaglutide and Liraglutide are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on the Regena Peptides site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.